Working… Menu
Trial record 8 of 433 for:    colon cancer AND Capecitabine

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04031872
Recruitment Status : Not yet recruiting
First Posted : July 24, 2019
Last Update Posted : July 24, 2019
Vall d'Hebron Institute of Oncology
European Organisation for Research and Treatment of Cancer - EORTC
Azienda Ospedaliera Niguarda Cà Granda
Fundación para la Investigación del Hospital Clínico de Valencia
University of Campania "Luigi Vanvitelli"
University of Turin, Italy
Eli Lilly and Company
Catalan Institute of Health
Universitaire Ziekenhuizen Leuven
Information provided by (Responsible Party):
The Netherlands Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021